NCT00707473View on ClinicalTrials.gov

Docetaxel, Cisplatin and Fluorouracil in Treating Patients With Previously Untreated Stage II-IV Nasal Cavity and Paranasal Sinus Cancer

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

June 16, 2008

Primary Completion Date

September 30, 2027

Study Completion Date

September 30, 2027

Conditions
Locally Advanced Nasal Cavity and Paranasal Sinus Squamous Cell CarcinomaNasal Cavity and Paranasal Sinus Poorly Differentiated CarcinomaSinonasal Undifferentiated CarcinomaStage II Nasal Cavity and Paranasal Sinus Cancer AJCC v8Stage III Nasal Cavity and Paranasal Sinus Cancer AJCC v8Stage IVA Nasal Cavity and Paranasal Sinus Cancer AJCC v8Stage IVB Nasal Cavity and Paranasal Sinus Cancer AJCC v8
Interventions
DRUG

Carboplatin

Given IV

OTHER

Chemoradiotherapy

Undergo chemoradiotherapy

DRUG

Cisplatin

Given IV

PROCEDURE

Definitive Surgical Resection

Undergo surgery

DRUG

Docetaxel

Given IV

DRUG

Fluorouracil

Given IV

PROCEDURE

Quality-of-Life Assessment

Correlative studies

RADIATION

Radiation Therapy

Undergo radiation therapy

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER